Efficacy of Azetukalner in Focal Onset Seizure (FOS) Subtypes: Results From the Double-Blind, Placebo Controlled X-TOLE Study (P8-9.012)
Report the efficacy of azetukalner by focal seizure subtype in the double-blind Phase 2b X-TOLE study
Authors
- Jenny Qian
- Jacqueline A. French (ORCID: https://orcid.org/0000-0003-2242-8027)
- Emilio Perucca (ORCID: https://orcid.org/0000-0001-8703-223X)
- Gregory N. Beatch
- Cynthia L. Harden
- Christopher Kenney
- Constanza Luzon Rosenblut
Institutions
- The University of Melbourne (AU)
- Xenon Pharmaceuticals (Canada) (CA)
- Austin Health (AU)
- Monash University (AU)
- New York University (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000211297
- Primary Topic
- Epilepsy research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00